drugset / Trial / NCT00251199

VX-950 and Peginterferon for Hepatitis C

NCT00251199

Phase 1 Completed 20 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupDouble-blind

Summary

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Timeline

Start
2005-10
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Telaprevir Small molecule
Background Peginterferon alfa-2a Protein / enzyme biologic